Recent advances in Lynch syndrome
Lynch syndrome is one of the most common hereditary cancer predisposition syndromes and is associated with increased risks of colorectal and endometrial cancer, as well as multiple other cancer types. While the mechanism of mismatch repair deficiency and microsatellite instability and its role in Lynch-associated carcinogenesis has been known for some time, there have been significant advances recently in diagnostic testing and the understanding of the molecular pathogenesis of Lynch tumors. There is also an increased awareness that the clinical phenotype and cancer risk varies by specific mismatch repair mutation, which in turn has implications on surveillance strategies for patients. Even the treatment of Lynch-associated cancers has changed with the addition of immunotherapy for advanced disease. This progress report aims to review some of the many advances in epidemiology, molecular pathogenesis, diagnosis, clinical phenotype, cancer surveillance, treatment, and chemo- and immune-prevention strategies in the Lynch syndrome field over the past 5 years.
KeywordsLynch syndrome Cancer genetics Hereditary cancer syndromes
S. Syngal is a consultant for Myriad Genetics and has rights to an inventor portion of licensing revenues from PREMM5.
- 7.NCCN clinical practice guidelines in oncology: genetic/familial high risk assessment: colorectal. Version 1.2018. https://www.nccn.org/professionals/physician_gls/pdf/genetics_colon.pdf. Published July 12, 2018. Accessed 1 Aug 2018
- 12.Stoffel EM, Mangu PB, Gruber SB et al (2015) Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol 33(2):209–217. https://doi.org/10.1200/JCO.2014.58.1322 CrossRefGoogle Scholar
- 13.NCCN clinical practice guidelines in oncology: uterine neoplasm. Version 1.2019.https://www.nccn.org/professionals/physician_gls/pdf/uterine.pdf. Published October 17, 2018. Accessed 25 Oct 2018
- 14.SGO Clinical Practice Statement: Screening for Lynch Syndrome in Endometrial Cancer. https://www.sgo.org/clinical-practice/guidelines/screening-for-lynch-syndrome-in-endometrial-cancer/. Published March 2014. Accessed Oct 2018
- 24.Haraldsdottir S, Rafnar T, Frankel WL et al. Comprehensive population-wide detection of Lynch syndrome in Iceland. ASCO Meet Abstr. 2016Google Scholar
- 49.Latham Schwark A, Srinivasan P, Kemel Y et al (2018) Pan-cancer microsatellite instability to predict for presence of Lynch syndrome. J Clin Oncol 36(18_suppl):LBA1509–LBA1509. https://doi.org/10.1200/JCO.2018.36.18_suppl.LBA1509 CrossRefGoogle Scholar
- 54.ten Broeke SW, van der Klift HM, Tops CMJ et al. Cancer risks for PMS2 -associated Lynch syndrome. J Clin Oncol. https://doi.org/10.1200/JCO.2018.78.4777
- 56.Møller P, Seppälä T, Bernstein I et al (2017) Cancer incidence and survival in Lynch syndrome patients receiving colonoscopic and gynaecological surveillance: first report from the prospective Lynch syndrome database. Gut 66(3):464–472. https://doi.org/10.1136/gutjnl-2015-309675 CrossRefGoogle Scholar
- 60.Overman MJ, McDermott R, Leach JL et al (2017) Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 18(9):1182–1191. https://doi.org/10.1016/S1470-2045(17)30422-9 CrossRefGoogle Scholar
- 66.Majumder S, Shah R, Elias J et al (2018) A cancer vaccine approach for personalized treatment of Lynch syndrome. https://doi.org/10.1038/s41598-018-30466-x